Loading
Life sciences · Journal article
Frontiers in Pharmacology · October 27, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Colorectal cancer (CRC) remains one of the leading causes of cancer-related mortality worldwide, and its first-line chemotherapeutic, 5-fluorouracil (5-FU), is constrained by poor tumor selectivity, dose-limiting systemic toxicity, and the frequent emergence of drug resistance. Nanocarrier-based co-delivery of naturally derived, multi-targeted agents offers a promising strategy to enhance efficacy while limiting off-target harm. This study evaluated the antitumor effects of nanoformulated liposomal melittin peptides (LIP-MLT) and niosomal chrysin (NsCR), administered as monotherapy or as combined therapy (LIP-MLT/NsCR), against DMH-induced CRC in a rat model. CRC was induced by subcutaneous injection of DMH (1,2-dimethylhydrazine, 40 mg/kg, twice weekly) for 8 weeks. Sprague-Dawley rats (n = 120) were randomly divided into six groups: healthy control (CON); untreated colorectal tumour (CR-TUM); and DMH-induced rats treated with 5-fluorouracil (CR-TUM + FU5), liposomal melittin (CR-TUM + LIP-MLT), niosomal chrysin (CR-TUM + NsCR), or the combination (CR-TUM + LIP-MLT/NsCR). Oxidant/antioxidant status, inflammatory cytokines, and the transcriptional profiles of inflammatory, cell-cycle-arrest, apoptotic/antiapoptotic, cGAS – STING innate-sensing, mTOR, and angiogenesis/metastasis genes were assessed, together with histopathological and immunohistochemical evaluation. The untreated CR-TUM group showed pronounced tumor-markers elevation, anemia, oxidative damage, and a strong pro-inflammatory, immunosuppressive shift. Relative to CR-TUM, LIP-MLT/NsCR lowered the tumor markers CEA (3.1-fold), CA19-9 (3.5-fold), and CCSA (2.1-fold), and reduced the oxidative markers ROS (2.2-fold), MDA (1.8-fold), and NO (2.2-fold) while raising the antioxidants. It also decreased the pro-inflammatory mediators NF-κB (2.3-fold), IL - 1 β (2.4-fold), and TNF -α (1.7-fold) versus CR-TUM, reversing approximately 71% of the DMH-induced inflammatory signature. At the transcriptional level, the combination produced the strongest upregulation of the pro-apoptotic genes (Caspase-3, Caspase-8, BAX, and p53 ) with concurrent downregulation of the antiapoptotic mediators (Bcl-2, c- FLIP, and Survivin), and marked proliferative and metastatic drivers suppression, including CDK4, CDK6, cyclin D1, β-catenin, mTOR, MMP -9, and VEGF, alongside restoration of the CDK inhibitors p21, p27, and KLF4 and normalization of cGAS, STING, and IRF3 mRNA levels. LIP-MLT/NsCR further best-preserved body weight and colon length, lowered diarrhea and rectal-bleeding scores, restored colonic histopathological architecture, and most strongly diminished the immunoexpression of MMP -9 and VEGF relative to untreated cancer tissues. Taken together, the combined LIP-MLT/NsCR nanoformulation attenuated DMH-induced CRC progression to a greater extent than either monotherapy or conventional 5-FU, supporting the combined melittin–chrysin nanoformulation as a promising, multi-targeted strategy against colorectal cancer.